Randhawa Simrat 4

Accession 0001992260-26-000002

CIK 0001690585other

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 5:40 PM ET

Size

5.5 KB

Accession

0001992260-26-000002

AI-generated summary of this filing

Updated Feb 4, 2026

Dianthus (DNTH) EVP Simrat Randhawa Receives 150,000-Share Award

What Happened

Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics (DNTH), was granted a derivative award covering 150,000 underlying shares on 2026-02-03. The reported acquisition price is $0.00 (no cash paid at grant). This is an award/grant (not a market purchase or sale).

Key Details

Transaction date: 2026-02-03; filing date: 2026-02-04 (timely filing).
Transaction type/code: Award/Grant (A); reported price per share: $0.00.
Shares underlying award: 150,000 common shares (derivative securities).
Shares owned after transaction: Not specified in the provided filing excerpt.
Footnote: Award vests in equal monthly installments over four years beginning January 1, 2026, subject to continued service (per filing footnote).

Context

This was a grant of derivative securities (an equity award) — not a sale or exercise — so it does not reflect an immediate cash transaction or disposition. The vesting schedule means shares will be delivered over time if Randhawa remains employed.

Form 4

Period: 2026-02-03

EVP, Head of R&D

Transactions

Award
Stock Option (Right to Buy)
[F1]
2026-02-03+150,000→ 150,000 total
Exercise: $52.46Exp: 2036-02-03→ Common Stock (150,000 underlying)

Footnotes (1)

[F1]The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Signature

/s/ Adam Veness, as attorney-in-fact for Simrat Randhawa|2026-02-04

1 file

Dianthus Therapeutics, Inc. /DE/

CIK 0001690585

Entity typeother